The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.
Joerg O W Pelz; Terence C Chua; Jesus Esquivel; Alexander Stojadinovic; Joerg Doerfer; David L Morris; Uwe Maeder; Christoph-Thomas Germer; Alexander G Kerscher (Profiled Author: Jesus Esquivel)
Department of General-, Visceral-, and Paediatric Surgery, University of Wuerzburg, Germany. firstname.lastname@example.org
BMC cancer 2010;10():689.
BACKGROUND: We evaluate the long-term survival of patients with peritoneal carcinomatosis (PC) treated with systemic chemotherapy regimens, and the impact of the of the retrospective peritoneal disease severity score (PSDSS) on outcomes. METHODS: One hundred sixty-seven consecutive patients treated with PC from colorectal cancer between years 1987-2006 were identified from a prospective institutional database. These patients either received no chemotherapy, 5-FU/Leucovorin or Oxaliplatin/Irinotecan-based chemotherapy. Stratification was made according to the retrospective PSDSS that classifies PC patients based on clinically relevant factors. Survival analysis was performed using the Kaplan-Meier method and comparison with the log-rank test. RESULTS: Median survival was 5 months (95% CI, 3-7 months) for patients who had no chemotherapy, 11 months (95% CI, 6-9 months) for patients treated with 5 FU/LV, and 12 months (95% CI, 4-20 months) for patients treated with Oxaliplatin/Irinotecan-based chemotherapy. Survival differed between patients treated with chemotherapy compared to those patients who did not receive chemotherapy (p = 0.026). PSDSS staging was identified as an independent predictor for survival on multivariate analysis [RR 2.8 (95%CI 1.5-5.4); p < 0.001]. CONCLUSION: A trend towards improved outcomes is demonstrated from treatment of patients with PC from colorectal cancer using modern systemic chemotherapy. The PSDSS appears to be a useful tool in patient selection and prognostication in PC of colorectal origin.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Terence C Chua; Winston Liauw; Heng-Nung Koong; Jesus EsquivelAmerican journal of clinical oncology 2011;34(3):326-31.
Terence C Chua; David L Morris; Akshat Saxena; Jesus Esquivel; Winston Liauw; Joerg Doerfer; Christoph-Thomas Germer; Alexander G Kerscher; Joerg O W PelzAnnals of surgical oncology 2011;18(6):1560-7.
C H Smorenburg; G J Peters; C J van Groeningen; P Noordhuis; K Smid; A M G H van Riel; W Dercksen; H M Pinedo; G Giaccone
Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(1):35-42.
Appears in this Publication
Author of this Publication